NIBEC CO., LTD.
Financials
Valuation Metrics
NIBEC CO., LTD.'s Market Cap is ₩1543B. At end of 2025 it was ₩4269B. Ranked #933 of 2,410 in KR market (top 39%), #445 of 1,631 on KOSDAQ (top 27%), #110 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 48%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 154.27B KRW | KR#933/2,410 Sec#110/231 |
| Revenue | 22.60B KRW | KR#2,107/2,410 Sec#154/231 |
| Net Income | -45.4M KRW | KR—/2,410 Sec—/231 |
| Total Assets | 64.54B KRW | KR#2,058/2,410 Sec#175/231 |
| Net Assets | 47.95B KRW | KR#1,933/2,410 Sec#161/231 |
| Employees | 96 | KR#1,666/2,410 Sec#130/231 |
| Value | ||
| P/B | 3.22x | KR#2,169/2,410 Sec#178/231 |
| P/S | 6.82x | KR#2,232/2,410 Sec#157/231 |
| FCF Yield | 2.81% | KR#1,016/2,410 Sec#65/231 |
| Profitability | ||
| ROE | -0.09% | KR#1,551/2,410 Sec#107/231 |
| ROA | -0.07% | KR#1,555/2,410 Sec#107/231 |
| Op. Margin | -8.43% | KR#1,947/2,410 Sec#132/231 |
| Revenue Growth | -32.68% | KR#2,224/2,410 Sec#197/231 |
| Financial Health | ||
| Debt Ratio | 34.62% | KR#679/2,410 Sec#80/231 |
| Total Debt | 15.75B KRW | KR#1,474/2,410 Sec#124/231 |
| FCF | 4.33B KRW | KR#938/2,410 Sec#66/231 |
| Cash | 22.00B KRW | KR#1,195/2,410 Sec#83/231 |
| Current Ratio | 3.39x | KR#480/2,410 Sec#70/231 |
| Performance | ||
| 1Y Return | -66.37% | KR#2,225/2,410 Sec#211/231 |
| 1M Return | -15.08% | KR#1,408/2,410 Sec#144/231 |
| From 52W High | -75.01% | KR#2,183/2,410 Sec#196/231 |
| 1Y MDD | -76.67% | KR#2,202/2,410 Sec#192/231 |
| Trading | ||
| Volume | 10,609 shares | KR#1,267/2,410 Sec#128/231 |
| Trading Value | 143.4M KRW | KR#876/2,410 Sec#94/231 |
| Foreign Own. | 2.87% | KR#1,324/2,410 Sec#119/231 |
| Per Share | ||
| EPS | -4 KRW | KR—/2,410 Sec—/231 |
| BPS | 4,218 KRW | KR#1,636/2,410 Sec#117/231 |
Company Info
NIBEC, established in 2004, was founded to commercialize research from the Seoul National University College of Dentistry's Intelligent Bio-Interface Engineering Research Center. The company develops peptide-based drugs, convergence biomaterials, and protein engineering technology-based drugs, leveraging peptide-based drug delivery systems and biomaterial technology for tissue regeneration. Its dental bio-regeneration materials are sold globally through Straumann and Nobel Biocare, having received NMPA sales approval in China in 2020. NIBEC is headquartered in Jincheon-gun, Chungcheongbuk-do.